Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

(2020) Terence C. S. Ho et al.   JOURNAL OF MEDICINAL CHEMISTRY

Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells

(2019) Shiou-Sheng Chen et al.   Cell Death & Disease

Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma

(2019) Fangmin Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors

(2019) Pierre Autin et al.   Cancers

BMP-2 induces angiogenesis by provoking integrin α6 expression in human endothelial progenitor cells

(2018) Wei-Cheng Chen et al.   BIOCHEMICAL PHARMACOLOGY

Epigenetic agents in combined anticancer therapy

(2018) Zdeněk Kejík et al.   Future Medicinal Chemistry

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

(2018) Jie Zang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Functions and mechanisms of non-histone protein acetylation

(2018) Takeo Narita et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemical and structural biology of protein lysine deacetylases

(2017) Minoru YOSHIDA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes

(2016) Alex R. Maolanon et al.   CHEMBIOCHEM

Targeting Angiogenesis in Cancer Treatments: Where do we Stand?

(2016) Nenad Petrovic   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

The Adverse Effects of Sorafenib in Patients with Advanced Cancers

(2015) Ye Li et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase

(2015) Fan-Wei Peng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HDAC inhibitors still need a home run, despite recent approval

(2015) Malini Guha   NATURE REVIEWS DRUG DISCOVERY

Polypharmacology: Challenges and Opportunities in Drug Discovery

(2014) Andrew Anighoro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

(2014) Hiren Patel et al.   MedChemComm

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization

(2014) Kiyoshi Okamoto et al.   ACS Medicinal Chemistry Letters

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes

(2011) Patrick M Lombardi et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

Promises and challenges of anticancer drugs that target the epigenome

(2011) Inge Verbrugge et al.   Epigenomics

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

(2010) Kyle V. Butler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis

(2008) D. Gao et al.   SCIENCE